Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Page 1
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, Sanders DB, West NE, Goss CH, Flume PA, Heltshe SL, VanDevanter DR, LiPuma JJ. Thornton CS, et al. Among authors: goss ch. Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC. Ann Am Thorac Soc. 2024. PMID: 37963297 Clinical Trial.
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and longer median time to next PEx (255 d vs. 172 d; P = 0.021) compared with virus negativity.Conclusions: More than one-third of STOP2 participant …
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and long …
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Szczesniak R, Andrinopoulou ER, Su W, Afonso PM, Burgel PR, Cromwell E, Gecili E, Ghulam E, Goss CH, Mayer-Hamblett N, Keogh RH, Liou TG, Marshall B, Morgan WJ, Ostrenga JS, Pasta DJ, Stanojevic S, Wainwright C, Zhou GC, Fernandez G, Fink AK, Schechter MS. Szczesniak R, et al. Among authors: goss ch. Ann Am Thorac Soc. 2023 Jul;20(7):958-968. doi: 10.1513/AnnalsATS.202209-829OC. Ann Am Thorac Soc. 2023. PMID: 36884219
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term follow-up (both were 1.4). Rate of decline estimates from nonlinear models diverged by age 30. ...Conclusions: Differences were as high …
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term …
The lung allocation score and other available models lack predictive accuracy for post-lung transplant survival.
Brahmbhatt JM, Hee Wai T, Goss CH, Lease ED, Merlo CA, Kapnadak SG, Ramos KJ. Brahmbhatt JM, et al. Among authors: goss ch. J Heart Lung Transplant. 2022 Aug;41(8):1063-1074. doi: 10.1016/j.healun.2022.05.008. Epub 2022 May 20. J Heart Lung Transplant. 2022. PMID: 35690561 Free PMC article.
BACKGROUND: Improved predictive models are needed in lung transplantation in the setting of a proposed allocation system that incorporates longer-term post-transplant survival in the United States. Allocation systems require accurate mortality predictions to justly allocat …
BACKGROUND: Improved predictive models are needed in lung transplantation in the setting of a proposed allocation system that incorporates l …
Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
Ramos KJ, Guimbellot JS, Valapour M, Bartlett LE, Wai TH, Goss CH, Pilewski JM, Faro A, Diamond JM; CFLTC Study Group. Ramos KJ, et al. Among authors: goss ch. J Cyst Fibros. 2022 Sep;21(5):745-752. doi: 10.1016/j.jcf.2022.04.009. Epub 2022 Apr 23. J Cyst Fibros. 2022. PMID: 35474016 Free PMC article.
Further study is needed to determine the risks and benefits of ETI in the CF lung transplant population given the potential for drug interactions, side effects leading to discontinuation of ETI, and the possible mechanisms for ETI to positively impact long-term post-transp …
Further study is needed to determine the risks and benefits of ETI in the CF lung transplant population given the potential for drug interac …
Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community.
Kapnadak SG, Morrell ED, Wai TH, Goss CH, Shah PD, Merlo CA, Hachem RR, Ramos KJ. Kapnadak SG, et al. Among authors: goss ch. J Heart Lung Transplant. 2022 Jan;41(1):20-23. doi: 10.1016/j.healun.2021.10.008. Epub 2021 Oct 22. J Heart Lung Transplant. 2022. PMID: 34785136 Free PMC article.
Chronic lung allograft dysfunction (CLAD) is the most important long-term complication after lung transplant (LTx), and clinical experience suggests significant variability in its management. ...
Chronic lung allograft dysfunction (CLAD) is the most important long-term complication after lung transplant (LTx), and clinical expe …
The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ, Heltshe SL, Skalland M, Lechtzin N, Nichols D, Goss CH. VanDevanter EJ, et al. Among authors: goss ch. J Cyst Fibros. 2021 Nov;20(6):932-936. doi: 10.1016/j.jcf.2021.02.012. Epub 2021 Mar 5. J Cyst Fibros. 2021. PMID: 33685776 Free PMC article. Clinical Trial.
BACKGROUND: Retrospective studies indicate that more cystic fibrosis (CF) pulmonary exacerbations (PEx) are treated with oral (PO) than with intravenous (IV) antimicrobials despite little knowledge of the relative effects of PO treatment on lung function recovery or long-term …
BACKGROUND: Retrospective studies indicate that more cystic fibrosis (CF) pulmonary exacerbations (PEx) are treated with oral (PO) than with …
Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis.
Somayaji R, Goss CH. Somayaji R, et al. Among authors: goss ch. Curr Pulmonol Rep. 2019 Dec;8(4):160-165. doi: 10.1007/s13665-019-00235-w. Epub 2019 Nov 26. Curr Pulmonol Rep. 2019. PMID: 31875166 Free PMC article.
PURPOSE OF REVIEW: a)We conducted a review of the current evidence relating to antibiotic duration in the short and long-term management of non-cystic fibrosis bronchiectasis. RECENT FINDINGS: b)In non-cystic fibrosis pulmonary exacerbations, evidence is primarily based on …
PURPOSE OF REVIEW: a)We conducted a review of the current evidence relating to antibiotic duration in the short and long-term managem …
Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis.
Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, Somayaji R, Heltshe SL. Nichols DP, et al. Among authors: goss ch. Am J Respir Crit Care Med. 2020 Feb 15;201(4):430-437. doi: 10.1164/rccm.201906-1206OC. Am J Respir Crit Care Med. 2020. PMID: 31661302 Free PMC article.
Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short controlled clinical trials showing reductions in pulmonary exacerbations and improved FEV(1). Long-term effects are unknown.Objectives: Examine pulmonary outcomes among chronic azithromycin …
Rationale: Chronic azithromycin is commonly used in cystic fibrosis based on short controlled clinical trials showing reductions in pulmonar …
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Konstan MW, et al. Among authors: goss ch. Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21. Lancet Respir Med. 2017. PMID: 28011037 Clinical Trial.
BACKGROUND: The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs)-TRAFFIC and TRANSPORT-in patients with cystic fibrosis who were aged 12 years or older and homozygous for the F508del-CFTR mutation. We aim …
BACKGROUND: The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs) …
23 results